Immunoglobulins

A patient with severe and recurrent pemphigus vulgaris achieved lasting remission with a novel intravenous immunoglobulin preparation that had the added benefit of reducing treatment-related side effects.

Intravenous immunoglobulin was effective as an adjunctive treatment to anticoagulation in a patient with post-viral platelet-activating anti-PF4 disorder, indicating the need for accurate diagnosis and treatment selection.

By developing the Shizuoka score, which features a new predictive model using machine learning, patients with Kawasaki disease who are non-responders to intravenous immunoglobulin were able to be accurately identified.

In a rare case of non-tumor anti-Tr/DNER antibody-associated ataxia, the patient is treated with plasmapheresis and intravenous immunoglobulin (IVIG) for symptoms such as dysarthria and difficulty walking.

With this approval, Yimmugo is the first approved product from the Biotest Next Level production facility.

The IVIG therapies were previously approved for 4-week room temperature storage conditions of 25º Celsius during the first 24 months of shelf life.

Bivigam was initially approved by the FDA in May 2019 for the treatment of primary humoral immunodeficiency, including a group of genetic disorders.

The approval marks the first and only once-daily target therapy for generalized myasthenia gravis for self-administration in this patient population.

Choice of therapy should be selected based on patient needs and conditions.

Intravenous immunoglobulin could potentially be given throughout the duration of anti-BCMA bispecific antibody therapy for the treatment of multiple myeloma.

Intravenous immunoglobulin found to provide fast and long-lasting relief for COVID-19-related neurological conditions, although investigators are still uncovering the pathology of many of these conditions.

The analysis results showed no statistically significant impact on either outcome, but results from prior prospective studies suggest that intravenous immunoglobulin may lengthen hospital stay for patients with severe COVID-19.

Bispecific antibodies have 2 distinct binding domains, which interact with either CD3 on T cells or a tumor-associated antigen on the tumor cell surface.

One IVIG product showed overall improvement in neuroprotection, including alleviating cognitive decline and ameliorating AB deposition in Alzheimer disease.

Research into the mechanisms of intravenous immunoglobulin is often challenging due to the complexity of polyclonal preparations, including diversity, repertoires, blocking, or anti-idiotypic antibodies.

Multiple studies show that it might be more effective to administer intravenous immunoglobulins at an earlier stage of disease progression.

Although the patient demographics are similar for the 3 categories of hemolytic reactions with intravenous immunoglobulin, the reaction with delayed hemolytic transfusion reactions was highest compared to the other 2 hemolytic reactions.

Relapses of MIS-C occurred in 2 patients due to rapid tapering of corticosteroids at 2 weeks instead of the standard protocol of 4 to 6 weeks.

The model was the first to incorporate C-reactive protein/albumin ratio and apply LASSO regression analysis to a predictive model for children with Kawasaki disease.

Intravenous immunoglobulin was found to be the most effective immunotherapy in preventing relapses after treatment with steroids in pediatric patients.

After repeated treatment with packed red blood cell transfusions, treatment with intravenous immunoglobulin in a child with parvovirus B19 infection successfully resolved the infection and negated the need for further transfusions.

Ervebo was found to be 100% effective after vaccination in preventing the onset of Ebola virus symptoms after more than 10 days.

With an intravenous immunoglobulin-based treatment protocol, individuals who underwent renal transplantation and who were presensitized achieved intermediate-term graft and recipient survival results at 98%.

It was previously undetermined whether the combination of IVIG and ICI would lead to patient complications or reduced efficacy of the cancer treatment, but 2 successful case reports dispel that belief.

High doses of intravenous immunoglobulin can result in expensive medical treatments for the families of children with immune thrombocytopenia.

Evidence remains limited for specific therapies to treat the disease, but new clinical trials are ongoing.

Intravenous immunoglobulin independently contributed to the reduction of pathogenic autoantibody levels associated with vasculitis in patients with severe kidney injury, a new study shows.

Albumin is a cost-effective predictor of intravenous immunoglobulin-resistance in young patients with Kawasaki disease.

Drug-induced myopathy is an underdiagnosed adverse effect of treatment with hydroxychloroquine with unclear treatment interventions other than discontinuing the drug.

Despite having a lower cost of development than the innovator, romiplostim biosimilar has comparable efficacy and safety in patients with chronic immune thrombocytopenia.